CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 6.1% – Here’s What Happened
by Jessica Moore · The Cerbat GemCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) dropped 6.1% during trading on Tuesday . The company traded as low as $50.26 and last traded at $50.3250. Approximately 1,023,693 shares changed hands during trading, a decline of 45% from the average daily volume of 1,865,190 shares. The stock had previously closed at $53.58.
Key Headlines Impacting CRISPR Therapeutics
Here are the key news stories impacting CRISPR Therapeutics this week:
- Positive Sentiment: CASGEVY sales showed growth and the company said its cash reserves strengthened after recent financing — a liquidity boost that supports ongoing R&D and commercial activities. CRISPR Therapeutics’ Q1 Loss Wider Than Expected, Sales Miss Estimates
- Positive Sentiment: Pipeline progress: management reported expansion of zugo‑cel into additional autoimmune indications and advancement of multiple in‑vivo liver‑directed programs toward the clinic — clinical advancement typically supports longer‑term value. Press Release: Q1 2026 Results & Business Update
- Neutral Sentiment: Broader sector note — Vertex (VRTX) reported stronger Q1 results and reaffirmed guidance; while not a CRISPR item, Vertex’s outperformance can shift investor attention within the gene/rare‑disease space. VRTX’s Q1 Earnings Beat Estimates
- Negative Sentiment: Q1 financial misses: CRISPR reported a loss per share of $1.28 vs. a consensus loss of ~$1.22 and revenue of $1.46M vs. ~$6.06M expected — a sizable revenue shortfall that pressured the stock. Zacks: Q1 Loss Wider Than Expected, Sales Miss
- Negative Sentiment: Large negative margins and still‑negative profitability metrics highlight that CRSP remains pre‑profitability and reliant on cash raises and product ramp to reach break‑even. Earnings recap: revenue & EPS surprises
Analysts Set New Price Targets
A number of research firms recently issued reports on CRSP. Evercore reiterated an “outperform” rating and set a $74.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Needham & Company LLC boosted their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Citizens Jmp decreased their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, TD Cowen boosted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $64.53.
Read Our Latest Research Report on CRSP
CRISPR Therapeutics Stock Performance
The company has a market capitalization of $5.05 billion, a P/E ratio of -8.03 and a beta of 1.75. The business has a 50 day moving average of $52.43 and a 200-day moving average of $54.74.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $6.06 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business’s revenue for the quarter was up 68.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.58) earnings per share. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -4.93 EPS for the current fiscal year.
Insiders Place Their Bets
In other CRISPR Therapeutics news, insider Naimish Patel sold 3,150 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the transaction, the insider directly owned 13,143 shares in the company, valued at $634,281.18. This represents a 19.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 3,450 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $166,497.00. Following the completion of the transaction, the general counsel owned 91,240 shares in the company, valued at $4,403,242.40. This represents a 3.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 51,828 shares of company stock worth $2,578,097 in the last ninety days. 4.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On CRISPR Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. Canal Insurance CO bought a new position in CRISPR Therapeutics in the 1st quarter worth about $1,670,000. CAP Partners LLC bought a new position in CRISPR Therapeutics in the 1st quarter worth about $205,000. Gables Capital Management Inc. bought a new position in CRISPR Therapeutics in the 1st quarter worth about $190,000. SFE Investment Counsel increased its stake in CRISPR Therapeutics by 12.1% in the 1st quarter. SFE Investment Counsel now owns 14,120 shares of the company’s stock worth $672,000 after acquiring an additional 1,520 shares during the last quarter. Finally, Farrow Financial Inc. increased its stake in CRISPR Therapeutics by 5.3% in the 1st quarter. Farrow Financial Inc. now owns 16,979 shares of the company’s stock worth $808,000 after acquiring an additional 849 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.